scout

June 2016

Radiation Dose Escalation to the Tumor-Arterial Interface of Locally Advanced and Borderline Resectable Pancreatic Cancer

ByMartin C. Tom, MD,Eugene J. Koay, MD, PhD, MD Anderson Cancer Center,Priya Bhosale, MD,Prajnan Das, MD, MPH,Matthew H. Katz, MD,Jason B. Fleming, MD,Jeffrey E. Lee, MD,Gauri R. Varadhachary, MD,Robert A. Wolff, MD,Christopher H. Crane, MD

An integrated boost with conventional fractionation to the tumor-arterial interface is unlikely to lead to downstaging in borderline resectable and locally advanced pancreatic cancer.

Hypofractionated and Stereotactic Body Radiotherapy in Prostate Cancer

ByChirag Shah, MD,Kevin Stephans, MD,Aditya Juloori, MD,Andrew Vassil, MD,Constantine Mantz, MD,Alvaro Martinez, MD,Frank Vicini, MD,Eduardo Fernandez, MD,Rahul D. Tendulkar, MD,Steven E. Finkelstein, MD

Despite limited data comparing stereotactic body radiation therapy to standard or hypofractionated radiotherapy with regards to long-term clinical outcomes and toxicity profiles, the data are promising and appropriately selected patients can be offered such an approach off-protocol.